Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Rinzimetostat · ORIC-944, MRTX-2219

Small molecule · Inhibitor of EED · developed by ORIC Pharmaceuticals

Phase 3 Most advanced trial
ORIC Developer
2 Registered trials

What is Rinzimetostat?

Rinzimetostat is an orally bioavailable allosteric inhibitor of the EED subunit of polycomb repressive complex 2 (PRC2). It prevents PRC2-mediated methylation of histone H3 at lysine 27, depleting H3K27me3 and modulating target gene expression to inhibit tumor cell proliferation. It is studied in metastatic prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ORIC-944, MRTX-2219
Drug type
Small molecule
Targets
EED, H3K27 (secondary target)
Mechanism
Inhibitor of EED
Pathways
H3K27 methylation, PRC2 activity, histone methylation
Therapy area
Oncology
Developer
ORIC Pharmaceuticals (ORIC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
9X4NP88TGB

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07723248 Phase 3 Metastatic Castration Resistant Prostate Cancer Recruiting ORIC
NCT05413421 Phase 1 Metastatic Prostate Cancer Recruiting ORIC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration Resistant Prostate CancerMetastatic Prostate Cancer

Other drugs acting on EED

APG-5918 Phase 1

More from ORIC Pharmaceuticals

Enozertinib Phase 1/2 ORIC-101 Phase 1 ORIC-533 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ORIC page.

Follow ORIC, the company behind Rinzimetostat

See ORIC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ORIC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.